Risk and Volatility
Acerus Pharmaceuticals has a beta of 2.6, meaning that its stock price is 160% more volatile than the S&P 500. Comparatively, Evelo Biosciences has a beta of 2.03, meaning that its stock price is 103% more volatile than the S&P 500.
Earnings & Valuation
This table compares Acerus Pharmaceuticals and Evelo Biosciences”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Acerus Pharmaceuticals | $7.38 million | 7.71 | -$18.79 million | ($0.08) | -2.75 |
| Evelo Biosciences | N/A | N/A | -$114.53 million | ($8.81) | N/A |
Insider and Institutional Ownership
0.0% of Acerus Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.3% of Evelo Biosciences shares are owned by institutional investors. 1.0% of Evelo Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Profitability
This table compares Acerus Pharmaceuticals and Evelo Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Acerus Pharmaceuticals | -254.66% | -346.72% | -94.54% |
| Evelo Biosciences | N/A | N/A | N/A |
Summary
Evelo Biosciences beats Acerus Pharmaceuticals on 6 of the 10 factors compared between the two stocks.
About Acerus Pharmaceuticals
Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Elegant vaginal moisturizer, which provides comfort to women suffering from vaginal dryness; and Elegant pH, a pH balanced vaginal product; Gynoflor, an ultra-low dose vaginal estrogen combined with a probiotic for the treatment of vaginal atrophy, restoration of vaginal flora, and treatment of certain vaginal infections; and Tefina, a clinical stage product for women with female sexual dysfunction. Acerus Pharmaceuticals Corporation sells products through its salesforce in Canada; and through a network of licensed distributors in the United States and internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.
About Evelo Biosciences
Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Acerus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acerus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
